Sanofi Vaccines US Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Sep 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Neisseria Meningitidis Vaccine (US 11,707,514) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for Stabilization of Vaccines by Lyophilization (US 9,132,184) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 2 fees due Apr 3, 2027
- 1 fee due May 28, 2027The maintenance fee for Methods of Optimizing Nucleotide Sequences Encoding Engineered Influenza Proteins (US 11,827,668) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Modification of Engineered Influenza Hemagglutinin Polypeptides (US 11,904,012) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Engineered Influenza Antigenic Polypeptides and Immunogenic Compositions Thereof (US 10,584,148) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Oct 26, 2027The maintenance fee for Pharmaceutical Compositions Containing Clostridium Difficile Toxoids A and B (US 9,320,790) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Pharmaceutical Compositions Containing Clostridium Difficile Toxoids a and B (US 10,639,362) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Sep 1 US D1,146,012 Nasal Vaccination Device
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,687,541 | Pharmaceutical Compositions Containing Clostridium Difficile Toxoids a and B In force · Medium confidence | In force | Medium confidence | |
| US 10,639,362 | Pharmaceutical Compositions Containing Clostridium Difficile Toxoids a and B In force · High confidence | In force | High confidence | |
| US 9,023,319 | Vaccine In force · High confidence | In force | High confidence | |
| US 9,132,184 | Stabilization of Vaccines by Lyophilization In force · High confidence | In force | High confidence | |
| US 9,320,790 | Pharmaceutical Compositions Containing Clostridium Difficile Toxoids A and B In force · High confidence | In force | High confidence | |
| US 10,160,797 | Antibodies Against Clostridium Difficile Toxins and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 11,220,537 | Antibodies Against Clostridium Difficile Toxins and Methods of Using the Same In force · Medium confidence | In force | Medium confidence | |
| US 11,419,930 | Compositions and Methods for Immunizing Against C. Difficile In force · Low confidence | In force | Low confidence | |
| US 12,116,402 | Antibodies Against Clostridium Difficile Toxins and Methods of Using the Same In force · Medium confidence | In force | Medium confidence | |
| US 10,584,148 | Engineered Influenza Antigenic Polypeptides and Immunogenic Compositions Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 34: 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.